biostudies-literatureUnknown4(9)Chen CT<h4>Purpose</h4>In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial.<h4>Patients and methods</h4>The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel.<h4>Results</h4>ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when combCancer research communications2415-2426https://www.ebi.ac.uk/biostudies/studies/S-EPMC11396014biostudies-literatureORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.PMC11396014Hamilton EOrr DWWang JBarkund SRKummar SAbdul-Karim RMDavis SLKhanna VPatel MRChen CTUeno NTDaemen AZhou HMultani PSXu RSommerhalder DSun JDMunster PNChow Maneval EJahchan NSJunttila MRPankov AFlorou VDuff MSpira AIJauhari SJackson ELTolcher AWKong WfalseORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.<h4>Purpose</h4>In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist that was investigated in combination with taxane chemotherapy as an anticancer regimen preclinically and in a phase 1 clinical trial.<h4>Patients and methods</h4>The ability of ORIC-101 to reverse taxane resistance was assessed in cell lines and xenograft models, and a phase 1 study (NCT03928314) was conducted in patients with advanced solid tumors to determine the dose, safety, and antitumor activity of ORIC-101 with nab-paclitaxel.<h4>Results</h4>ORIC-101 reversed chemoprotection induced by glucocorticoids in vitro and achieved tumor regressions when comb2024-01-01T00:00:00Z2024 Sep2026-06-30T03:16:23.151Z2025-04-04T11:04:10.124ZS-EPMC113960143917728510.1158/2767-9764.CRC-24-0115